One more chemo or one too many? Defining the limits of treatment and innovation in medical oncology

Social Science and Medicine

Volumn 75, Issue 5, 2012, Pages 864-872

  Baszanger, Isabelle ^a  

^a CNRS   (France)

Author keywords

Advanced cancer; Chemotherapy; Cure; Decision making; End of life care; History of chemotherapy; Inteerventions; Medical oncology; Palliation; Pursuing withdrawing treatment

Indexed keywords

CANCER; DECISION MAKING; DISEASE TREATMENT; ETHICS; HEALTH CARE; STAKEHOLDER;

ARTICLE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER THERAPY; GROUNDED THEORY; HOSPICE CARE; MEDICAL DECISION MAKING; PHYSICIAN ATTITUDE; QUALITY OF LIFE; TERMINAL CARE; TREATMENT DURATION; TREATMENT PLANNING;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; THERAPIES, INVESTIGATIONAL;

EID: 84862753796     PISSN: 02779536     EISSN: 18735347     Source Type: Journal    
DOI: 10.1016/j.socscimed.2012.03.023     Document Type: Article

References (65)

1. Archer V.R., Billingham L.J., Cullen M.H. Palliative chemotherapy: no longer a contradiction in terms. The Oncologist 1999, 4:470-477.
2. At a glance CA: A Cancer Journal for Clinicians 1959, 9:74-81.
3. At a glance CA: A Cancer Journal for Clinicians 1960, 10:2-8.
4. Armstrong, et al. Health-related quality of life and the transformation of symptoms. Sociology of Health and Illness 2007, 29:570-583.
5. Bahls C., Fogarty M. Reining in a Killer disease. The Scientist 2002, 16(11):16-18.
6. Bailar J.C. Rethinking the war on cancer. New England Journal of Medicine 1986, 314:1226-1232.
7. Baszanger I. Entre traitement de la dernière chance et palliatif pur: les frontières invisibles des innovations thérapeutiques. Sciences sociales et santé 2000, 18:67-94.
8. Baszanger I. La fin de la vie: De nouvelles frontières entre curatif et palliatif. Quelle médecine voulons-nous ? 2002, 211-233. La dispute, Paris. I. Baszanger, M. Bungener, A. Paillet (Eds.).
9. Baszanger, I., & Szabo, J. (2011). Making sense of time-reconfiguring cancer as a chronic disease. Paper for the Workshop " Between the medical and the social: Institutions of Chronic Disease and Disability in the Twentieth Century" , Paris: 8-10 December.
10. Bertino J. Editorial: a journal for oncologists. Journal of Clincial Oncology 1983, 1:1.
11. Braverman A.S. Medical oncology in the 1990s. Lancet 1991, 333(8746):901-902.
12. Bruck L. Cancer as a chronic condition. Implications for pratice published on line March 2nd, last accessed 04.11.11. http://www.onclive.com.
13. Bruera E. 9th International MASCC symposium supportive care in cancer: an interview with Dr Eduardo Bruera from the palliative care program in Edmonton. Supportive Care Cancer 1997, 5:263-264.
14. Cancer in the twentieth century. Bulletin of The History of Medicine 2007, Special issue.
15. Cantor, D. (2009). The moment of recovery in twentieth century american cancer campaigns. Paper for the workshop: How cancer changed: expanding the boundaries of medical interventions, Paris, 2-3 April.
16. Chabner B. The oncologic end game. Journal of Clinical Oncology 1986, 4:625-638.
17. Chow E., Abdolell M., Panzarella T., Harris K., Bezjak A., Warde P., et al. Predicitive model for survival in patients with advanced cancer. Journal of Clincial Oncology 2008, 26:5863-5869.
18. Clark D. An annotated bibliography of the publications of Ciceley Sauders-1: 1958-67. Palliative Medicine 1998, 12:1981-1993.
19. Clark D. From margins to centre: a review of the history of palliative care in cancer. Lancet Oncology 2007, 8:430-438.
20. Clarke A. Situational analysis. Grounded theory after the postmodern turn 2005, Sage Inc, Thousand Oaks.
21. DelVecchio-Good M.-J., Good B., Schaffer C., Lind S. Oncology and the discourse on hope. Culture, Medicine & Psychiatry 1990, 14(1):59-79.
22. Dunphy J.E. On caring for the patient with cancer. CA: A Cancer Journal for Clinicians 1977, 27:109-113.
23. Earle C., Park E., Lai B., Weeks J., Ayanian J., Block S. Identifying potential indicators of the quality of end-of-life cancer care administrative data. Journal of Clinical Oncology 2003, 21:1133-1138.
24. Earle C., Landrum M., Souza J., Neville B., Weeks J., Ayanian J. Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?. Journal of Clinical Oncology 2008, 26:3860-3866.
25. Freireich E., Kurzrock R. The role of investigational therapy in management of patients with adavanced metastatic maliganancy. Journal of Clinical Oncolog 2009, 27:304-306.
26. Fox R.C. Experiment perillous. Physicians and patients facing the unknown 1959, Free Press, Glencoe.
27. Fox R.C. The sting of death in American society. Social Service Review 1981, 55:42-59.
28. Fox R.C. Medical uncertainty revisited. The handbook of social studies in health and medicine 2000, 409-425. Sage, London. G.L. Albrecht, R. Fitzpatrick, S.C. Scrimshaw (Eds.).
29. Fox R., Swazey J. Observing bioethics 2008, Oxford University Press, New York.
30. Ganz P., Filgin R., Haskell C., La Soto N., Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer 1989, 63:1271-1278.
31. Goldwasser F. La chimiothérapie de trop 2008, Faculté de médecine Paris Descartes, Paris, DES-ppt.
32. Harrington S., Smith T. The role of chemotherapy at the end of life: 'when is enough, enough?'. Journal of American Medical Association 2008, 299:2667-2678.
33. Holland J. Breaking the cure barrier. Journal of Clinical Oncology 1983, 2:75-90.
34. Holleb A. The cancer patient-too often left alone. CA: A Cancer Journal for Clinicians 1972, 22:129.
35. Holleb A. A patient's right to die...The easy way out?. CA: A Cancer Journal for Clinicians 1974, 24:256.
36. Homburger F. Palliative medical therapy of cancer. CA: A Cancer Journal for Clinicians 1956, 6:96-99.
37. Illich I. Medical nemesis 1974, Calder & Boyars, London.
38. Karnofsky D. Chemotherapy of cancer. CA: A Cancer Journal for Clinicians 1955, 5:165-173.
39. Karnofsky D. Why prolong the life of a patient with advanced cancer?. CA: A Cancer Journal for Clinicians 1960, 10:9-11.
40. Karnofsky D. Rationale for aggressive or extraordinary means of treatment of advanced cancer. CA: A Cancer Journal for Clinicians 1962, 12:166-170.
41. Karnofsky D. Palliation and life prolongation with anticancer drugs. CA: A Cancer Journal for Clinicians 1966, 16:117-119.
42. Keating P., Cambrosio A. Cancer clinical trials: the emergence and development of a new style of practice. Bulletin of The History of Medicine 2007, 81(1). 1997-233.
43. Keating P., Cambrosio A. Cancer on trial: Oncology as a new style of practice 2012, The University of Chicago Press, Chicago.
44. Krakoff I. The case for active treatment in patients with advanced cancer: not everyone needs a hospice. CA: A Cancer Journal for Clinicians 1979, 29:108-111.
45. Krant M. Rights of the cancer patient. CA: A Cancer Journal for Clinicians 1975, 25:98-100.
46. Löwy I. Between bench and bedside: Science, healing, and Interlukine-2 in a cancer ward 1996, Harvard University Press, Harvard.
47. Löwy I. Preventive strikes: Women, precancer, and prophylactic surgery 2009, The Johns Hopkins University Press.
48. McKeown T. The role of medicine: Dream, mirage, or nemesis? 1976, Nuffield Provincial Hospitals Trust, London, England.
49. Markman M. Palliative chemotherapy " near the end-of-life" in ovarian cancer: not necessarily " aggressive cure-oriented therapy" Gynecology & Oncology 2006, 101(2):198-199.
50. No hopeless patients...only physicians without hope. Editorial, CA: A Cancer Journal for Clinicians 1959, 9:5.
51. Payne L. Guerir quelquefois, Soulager souvent, Consoler toujours. British Medical Journal 1967, 4:47-48.
52. Patterson J. The dread disease. Cancer and modern American culture 1987, Harvard University Press, Cambridge.
53. Potter J. A challenge for the hospice movement. NEJM 1980, 302(1):53-55.
54. Rynearson E. You are standing at the bedside of a patient dying of untreatable cancer. CA: A Cancer Journal for Clinicians 1959, 9:85-87.
55. Saunders C. Drug treatment of patients in the terminal satges of cancer. Current Medicine and Drugs 1960, 1:16-28.
56. Saunders C. The care of the dying. Gerontologica Clinica 1967, 9:385-390.
57. Scheithauer W., Rosen H., Kornek G., Sebesta C., Depisch D. Randomised compraison of combination therapy plus supportive care with supportive care alone in patients with matastatic colorectal ceancer. British Medical Journal 1993, 306:752-755.
58. How worthwhile is noncurative chemotherapy 1998, Springer-Verlag Publications, London. M.L. Slevin, T. Tate (Eds.).
59. Shanafelt T., Loprinzi C., Marks R., Novotny P., Sloan J. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?. Journal of Clinical Oncology 2004, 22:1966-1974.
60. Shepherd S., Perira J., Ciuleanu T., Tan E., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small celle lung cancer. New England Journal of Medicine 2008, 353(2):123-132.
61. Spencer H., Laszlo D. Problems in the management of patients with advanced cancer. CA: A Cancer Journal for Clinicians 1953, 3:14-18.
62. Strauss A. Qualitative analysis for social scientists 1987, Cambridge University Press, Cambridge, UK.
63. Szabo J. Incurable and intolerable. Chronic disease and slow death in nineteenth-century France 2009, Rutgers University Press, New Brunswick, NJ.
64. Time Medicine: cancer & conscience Friday, Nov 03. http://www.time./time/magazine/article/.
65. Weisz G. Divide and conquer. A comparative history of medical specialization 2006, Oxford University Press, New York.